Introduction: PLASMIC and French scores have been developed to help clinicians in the early identification of patients with thrombotic thrombocytopenic purpura (TTP). Nevertheless, the validity of these scores in thrombotic microangiopathy (TMA) cohorts with low TTP prevalence remains uncertain. We aimed to evaluate their diagnostic value in routine clinical practice using an unselected cohort of patients with TMA. We also analyzed the value of adding proteinuria level to the scores.

Methods: We retrospectively included all patients presenting with a biological TMA syndrome between January 1, 2008, and December 31, 2019, in a tertiary hospital. TMA etiology was ascertained, and scores were evaluated. Modified scores, built by adding 1 point for low proteinuria (<1.2 g/g), were compared with original scores for TTP prediction.

Results: Among 273 patients presenting with a full biological TMA syndrome, 238 were classified with a TMA diagnosis. Complete scores and proteinuria level were available in 134 patients with a TTP prevalence of 7.5%. Area under the receiver operating characteristic curve (AUC) of PLASMIC and French scores for TTP diagnosis was 0.65 (0.46-0.84) and 0.72 (0.51-0.93), respectively. AUC of modified PLASMIC and French scores was 0.76 (0.59-0.92) ( = 0.003 vs. standard score) and 0.81 (0.67-0.95) ( = 0.069 vs. standard score), respectively. Specificity, positive predictive value (PPV), and positive likelihood ratio of high-risk scores were significantly improved by adding proteinuria level.

Conclusion: PLASMIC and French scores have low predictive values when applied to an unselected TMA cohort. Including proteinuria level in the original scores improves their performance for TTP prediction.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820983PMC
http://dx.doi.org/10.1016/j.ekir.2021.11.009DOI Listing

Publication Analysis

Top Keywords

plasmic french
8
french scores
8
thrombotic thrombocytopenic
8
thrombocytopenic purpura
8
patients thrombotic
8
thrombotic microangiopathy
8
scores
5
proteinuria increases
4
increases plasmic
4
scores performance
4

Similar Publications

Refining the standard of care in immune thrombotic thrombocytopenic purpura.

Clin Adv Hematol Oncol

October 2024

Division of Hematology and Medical Oncology, NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York, New York.

Article Synopsis
  • Acute immune thrombotic thrombocytopenic purpura (iTTP) is a serious condition that requires immediate medical attention and tests to see how it's affecting the blood.
  • Patients usually start treatment with plasma exchange (PE) and may also receive medications like glucocorticoids, rituximab, and caplacizumab to help improve their condition.
  • A study showed that using caplacizumab can reduce repeated episodes and speed up recovery, but there are some risks, like bleeding, which mostly get better on their own.
View Article and Find Full Text PDF
Article Synopsis
  • The main treatment for immune-mediated thrombotic thrombocytopenic purpura (iTTP) in children includes therapeutic plasma exchange (TPE), corticosteroids, and rituximab, while caplacizumab is used for older children and adults, but its use for those under 12 is not officially approved.
  • A case study of a 7-year-old girl with iTTP showed successful treatment with caplacizumab after adjusting the dose according to her ADAMTS13 activity, leading to significant clinical improvement and full recovery without major side effects.
  • The review of existing literature revealed five cases of iTTP in children under 12 treated with caplacizumab, all showing success and safety,
View Article and Find Full Text PDF

Objective: In recent years, new developments have been incorporated into daily practice in the management of immune thrombotic thrombocytopenic purpura (iTTP). In particular, clinical scoring systems could help clinicians with clinical decision-making and early recognition. However, older patients frequently present with more organ involvement and in unusual ways.

View Article and Find Full Text PDF

Challenges in the diagnosis of thrombotic thrombocytopenic purpura.

Expert Rev Hematol

November 2023

Department of Pathology, Division of Laboratory Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

Introduction: Immune-mediated TTP (iTTP) is a rare condition without pathognomonic signs and symptoms. For this reason, the diagnosis of iTTP may be delayed or even missed, with potentially catastrophic consequences.

Areas Covered: The authors performed an extensive literature review on the diagnosis of iTTP and its challenges combined with their own experience in a referral center for patients with iTTP.

View Article and Find Full Text PDF

Background: The improvement in the clinical care for patients with thrombotic thrombocytopenic purpura (TTP) is evolving, and many efforts are being put to standardize it. Here, we aimed to assess the provided care at a national level and identify deficiencies.

Methods: A national Saudi retrospective descriptive study was carried out at six tertiary referral centers and included all patients who underwent therapeutic plasma exchange (TPE) for the diagnosis of TTP between May 2005, and July 2022.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!